Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

VTGN

Vistagen Therapeutics (VTGN)

Vistagen Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VTGN
DateTimeSourceHeadlineSymbolCompany
01/14/20255:16PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
01/14/20258:30AMBusiness WireVistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer CachexiaNASDAQ:VTGNVistagen Therapeutics Inc
01/13/20255:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
01/13/20255:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
01/13/20255:28PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
01/10/20258:30AMBusiness WireVistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety DisorderNASDAQ:VTGNVistagen Therapeutics Inc
12/06/20244:49PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
11/14/20244:53PMEdgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
11/14/20244:19PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:VTGNVistagen Therapeutics Inc
11/14/20248:30AMBusiness WireVistagen to Present at the Stifel 2024 Healthcare ConferenceNASDAQ:VTGNVistagen Therapeutics Inc
11/07/20244:34PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistagen Therapeutics Inc
11/07/20244:20PMBusiness WireVistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
11/05/20248:30AMBusiness WireVistagen to Present at the 2024 Neuroscience Education Institute CongressNASDAQ:VTGNVistagen Therapeutics Inc
11/01/20248:30AMBusiness WireVistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024NASDAQ:VTGNVistagen Therapeutics Inc
10/09/20248:30AMBusiness WireVistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health DayNASDAQ:VTGNVistagen Therapeutics Inc
09/23/20248:49AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
09/23/20248:30AMBusiness WireVistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderNASDAQ:VTGNVistagen Therapeutics Inc
09/10/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
09/10/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
09/10/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
09/10/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistagen Therapeutics Inc
08/28/20244:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
08/13/20244:53PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
08/13/20244:49PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistagen Therapeutics Inc
08/13/20244:21PMBusiness WireVistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate UpdateNASDAQ:VTGNVistagen Therapeutics Inc
08/06/20248:30AMBusiness WireVistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024NASDAQ:VTGNVistagen Therapeutics Inc
07/12/20244:27PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
07/10/20244:34PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistagen Therapeutics Inc
07/09/20248:30AMBusiness WireVistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of MigraineNASDAQ:VTGNVistagen Therapeutics Inc
06/27/20248:30AMBusiness WireVistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive YearNASDAQ:VTGNVistagen Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VTGN